In Vitro Properties and Pharmacokinetics of Temporarily PEGylated Onc72 Prodrugs
Advanced Healthcare Materials · 2023-04 · 12 (11)
DOI: 10.1002/adhm.202202368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 20.01.2023. Verfasst von Gubran Khalil Mohammed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, 04103, Leipzig, Germany. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutscher Akademischer Austauschdienst, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
The favorable properties of antimicrobial peptides (AMPs) to rapidly kill pathogens are often limited by unfavorable pharmacokinetics due to fast degradation and renal clearance rates. Here, a prodrug strategy linking proline‐rich AMP Onc72 to polyethylene glycol (PEGs) with average molecular weights of 5 and 20 kDa via a peptide linker containing a protease cleavage site is tested for the first time in vivo. Onc72 is released from these 5k‐ and 20k‐prodrugs in mouse serum with half‐life times ( t 1/2 ) of 8 and 14 h, respectively. Importantly, PEGylation protects Onc72 from proteolytic degradation providing a prolonged release of Onc72, balancing the degradation of free Onc72, and leading to relatively stable Onc72 concentrations and high antibacterial activities. The prodrugs are not hemolytic on human erythrocytes and show only slight cytotoxic effects on human cell lines indicating promising safety margins. When administered subcutaneously to female CD‐1 mice, the prodrugs elimination t 1/2 are 66 min and ≈5.5 h, respectively, compared to 43 min of free Onc72. The maximal Onc72 plasma levels are obtained ≈1 and ≈8 h postadministration, respectively. In conclusion, the prodrugs provide extended elimination t 1/2 and a constant release of Onc72 in mice, potentially limiting adverse effects and increasing efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, 04103, Leipzig, Germany.
- Center for Biotechnology and Biomedicine, Leipzig University, 04103, Leipzig, Germany.
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
- EnBiotix GmbH, 04103, Leipzig, Germany.
ORCID-Profile: Ralf Hoffmann
Förderung
- Deutscher Akademischer Austauschdienst
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Mohammed, G. K., Böttger, R., Krizsan, A., Volke, D., Mötzing, M., Li, S. D., Knappe, D., & Hoffmann, R. (2023). In Vitro Properties and Pharmacokinetics of Temporarily PEGylated Onc72 Prodrugs. Advanced Healthcare Materials, 12(11). https://doi.org/10.1002/adhm.202202368
Vancouver
Mohammed GK, Böttger R, Krizsan A, Volke D, Mötzing M, Li SD, et al. In Vitro Properties and Pharmacokinetics of Temporarily PEGylated Onc72 Prodrugs. Advanced Healthcare Materials. 2023;12(11). doi:10.1002/adhm.202202368
BibTeX
@article{Mohammed2023,
author = {Mohammed, Gubran Khalil and Böttger, Roland and Krizsan, Andor and Volke, Daniela and Mötzing, Marina and Li, Shyh-Dar and Knappe, Daniel and Hoffmann, Ralf},
title = {In Vitro Properties and Pharmacokinetics of Temporarily PEGylated Onc72 Prodrugs},
journal = {Advanced Healthcare Materials},
year = {2023},
volume = {12},
number = {11},
doi = {10.1002/adhm.202202368}
}
EUVIMED